Background Most studies on MET exon 14 (MET-ex14) alteration, defined as an oncogenic
driver, have been carried out among Caucasians; similar studies among Chinese people …

Background: Alterations in MET exon 14 (METex14) and its flanking intronic regions have
been identified in a variety of cancers. Patients with METex14 alterations often benefit from …

MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs).
These alterations are associated with increased MET activity and preclinical sensitivity to …

Background MET-deregulated non-small cell lung cancer represents an urgent clinical need
because of the lack of specific therapies. Although recent studies have suggested a potential …

108 Background: MET alterations leading to exon 14 skipping occur in~ 4% of lung
carcinomas, resulting in MET activation and sensitivity to MET inhibitors in vitro. Crizotinib …

Objectives MET amplification or MET exon 14 skipping site mutation can be treated with
crizotinib in non-small cell lung cancer patients. Y1003 is a binding site for E3 ubiquitin …

The receptor tyrosine kinase MNNG-HOS transforming gene (MET) and its ligand
hepatocyte growth factor play an important role in normal cell biology as well as in a number …

Background MET alterations leading to exon 14 skipping occur in∼ 4% of non-squamous
non-small cell lung cancer (NSCLCs) and 20–30% of sarcomatoid lung carcinomas …

Introduction: Non-small cell lung cancer (NSCLC) accounts for most lung cancers and is a
leading cause of cancer-related deaths in the USA. Alterations in c-MET, a tyrosine kinase …

Objectives Although dramatic responses to MET inhibitors have been reported in patients
with MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC), the impact of …